CVE:LXG - Lexagene Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$0.88 -0.02 (-2.22 %)
(As of 07/20/2018 04:00 PM ET)
Previous CloseC$0.90
Today's RangeC$0.85 - C$0.93
52-Week RangeC$0.51 - C$1.64
Volume69,987 shs
Average Volume70,524 shs
Market CapitalizationC$63.63 million
P/E RatioN/A
Dividend YieldN/A
Beta-5.14
Lexagene Holdings Inc. engages in the research, development, and commercialization of pathogen detection devices to the bio-chemical industry in the United States. The company is headquartered in Vancouver, Canada.

Receive LXG News and Ratings via Email

Sign-up to receive the latest news and ratings for LXG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange CVE
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
SymbolCVE:LXG
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares58,914,000
Market CapC$63.63

Lexagene (CVE:LXG) Frequently Asked Questions

What is Lexagene's stock symbol?

Lexagene trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LXG."

What is the consensus analysts' recommendation for Lexagene?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexagene in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Lexagene's key competitors?

Who are Lexagene's key executives?

Lexagene's management team includes the folowing people:
  • Dr. John F. Regan, Founder, Chairman & CEO
  • Mr. Darrel M. Rebeck, Pres & Director
  • Mr. Jeffrey Mitchell, Chief Financial Officer
  • Mr. Allan Fabbro, VP of Corp. Devel.
  • Mr. Greg Dale, VP of Product Devel. & Manufacturing

Has Lexagene been receiving favorable news coverage?

Press coverage about LXG stock has trended positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Lexagene earned a coverage optimism score of 0.27 on Accern's scale. They also gave news coverage about the company an impact score of 47.02 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Lexagene?

Shares of LXG and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Lexagene's stock price today?

One share of LXG stock can currently be purchased for approximately C$0.88.

How big of a company is Lexagene?

Lexagene has a market capitalization of C$63.63 million.


MarketBeat Community Rating for Lexagene (CVE LXG)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  14 (Vote Outperform)
Underperform Votes:  16 (Vote Underperform)
Total Votes:  30
MarketBeat's community ratings are surveys of what our community members think about Lexagene and other stocks. Vote "Outperform" if you believe LXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Featured Article: Relative Strength Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.